Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-09-21 4:32 pm Purchase |
2023-09-11 | 13D | Dianthus Therapeutics, Inc. DNTH |
Fairmount Funds Management LLC | 1,873,833 12.700% |
1,873,833 (New Position) |
Filing History |
| 2023-08-10 4:15 pm Purchase |
2023-08-02 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
Fairmount Funds Management LLC | 2,143,052 6.100% |
2,143,052 (New Position) |
Filing History |
| 2023-07-21 4:31 pm Purchase |
2023-07-13 | 13D | Apogee Therapeutics, Inc. APGE |
Fairmount Funds Management LLC | 3,906,202 9.990% |
3,906,202 (New Position) |
Filing History |
| 2023-07-07 4:00 pm Purchase |
2023-06-28 | 13G | Axsome Therapeutics, Inc. AXSM |
Fairmount Funds Management LLC | 2,344,980 5.000% |
333,333 (+16.57%) |
Filing History |
| 2023-06-30 5:24 pm Purchase |
2023-06-22 | 13D | Aeglea BioTherapeutics, Inc. AGLE |
Fairmount Funds Management LLC | 783,600 19.990% |
783,600 (New Position) |
Filing History |
| 2023-06-13 4:06 pm Purchase |
2023-06-09 | 13D | Cogent Biosciences, Inc. COGT |
Fairmount Funds Management LLC | 19,962,564 19.990% |
4,732,091 (+31.07%) |
Filing History |
| 2023-04-27 10:00 am Purchase |
2023-04-18 | 13G | Enliven Therapeutics, Inc. ELVN |
Fairmount Funds Management LLC | 2,124,625 5.170% |
2,124,625 (New Position) |
Filing History |
| 2023-02-14 3:45 pm Purchase |
2022-12-31 | 13G | Annexon, Inc. ANNX |
Fairmount Funds Management LLC | 3,681,456 7.700% |
1,112,056 (+43.28%) |
Filing History |
| 2023-02-14 3:45 pm Sale |
2022-12-31 | 13G | Axsome Therapeutics, Inc. AXSM |
Fairmount Funds Management LLC | 2,011,647 4.600% |
-155,000 (-7.15%) |
Filing History |
| 2023-02-14 3:45 pm Purchase |
2022-12-31 | 13G | Astria Therapeutics, Inc. ATXS |
Fairmount Funds Management LLC | 1,901,397 6.900% |
989,661 (+108.55%) |
Filing History |
| 2023-02-14 3:45 pm Sale |
2022-12-31 | 13G | Olema Pharmaceuticals, Inc. OLMA |
Fairmount Funds Management LLC | 0 0.000% |
-2,107,873 (Position Closed) |
Filing History |
| 2023-02-14 3:45 pm Purchase |
2022-12-31 | 13G | Nuvalent, Inc. NUVL |
Fairmount Funds Management LLC | 2,788,981 5.470% |
183,857 (+7.06%) |
Filing History |
| 2023-02-14 3:45 pm Purchase |
2022-12-31 | 13G | Terns Pharmaceuticals, Inc. TERN |
Fairmount Funds Management LLC | 5,269,287 9.900% |
3,219,287 (+157.04%) |
Filing History |
| 2023-02-14 3:45 pm Purchase |
2022-12-31 | 13G | Trevi Therapeutics, Inc. TRVI |
Fairmount Funds Management LLC | 6,018,465 9.900% |
2,258,955 (+60.09%) |
Filing History |
| 2022-11-09 10:02 am Purchase |
2022-11-03 | 13G | Nuvalent, Inc. NUVL |
Fairmount Funds Management LLC | 2,605,124 5.130% |
2,605,124 (New Position) |
Filing History |
| 2022-10-25 9:09 pm Purchase |
2022-09-16 | 13G | Axsome Therapeutics, Inc. AXSM |
Fairmount Funds Management LLC | 2,166,647 5.400% |
2,166,647 (New Position) |
Filing History |
| 2022-08-25 09:32 am Purchase |
2022-08-16 | 13G | Terns Pharmaceuticals, Inc. TERN |
Fairmount Funds Management LLC | 2,050,000 5.450% |
2,050,000 (New Position) |
Filing History |
| 2022-08-19 4:34 pm Purchase |
2022-08-17 | 13D | Viridian Therapeutics, Inc. VRDN |
Fairmount Funds Management LLC | 9,192,814 19.990% |
5,732,463 (+165.66%) |
Filing History |
| 2022-06-21 10:04 am Purchase |
2022-06-16 | 13D | Cogent Biosciences, Inc. COGT |
Fairmount Funds Management LLC | 15,230,473 19.990% |
15,230,473 (New Position) |
Filing History |
| 2022-04-21 10:00 am Purchase |
2022-04-11 | 13G | Trevi Therapeutics, Inc. TRVI |
Fairmount Funds Management LLC | 3,759,510 9.900% |
3,759,510 (New Position) |
Filing History |